CytoSorbents To Provide Corporate Update at Biotech Showcase 2018

1/3/18

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will give a corporate update and discuss goals for 2018 at the Biotech Showcase™ 2018 conference on Tuesday, January 9, 2018 at 11:00 AM PST in San Francisco, California. Dr. Chan will be joined by Kathleen Bloch, Chief Financial Officer, Vincent Capponi, Chief Operating Officer, and Chris Cramer, Vice President of Business Development during the informal question and answer session that will follow.

About Biotech Showcase™

Biotech Showcase is one of the industry's largest annual healthcare investor and partnering conferences, with more than 3,500 attendees, 400 public and private company presentations, 2,100 companies, and more than 900 investors expected. Attendees include biopharmaceutical and life science company executives, investors in private and public companies, sector analysts, bankers and industry professionals. The conference is run concurrently with, but independently from, the JP Morgan Healthcare Conference in San Francisco, one of the largest and most influential international healthcare conferences.

Now in its tenth year, the Biotech Showcase™ features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy Colton Life Science Advisors and EBD Group.

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 44 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorbents has completed its REFRESH (REduction in FREe Hemoglobin) 1 trial – a multi-center, randomized controlled safety and feasibility study that has demonstrated that intra-operative CytoSorb® use in a heart-lung machine during complex cardiac surgery can significantly reduce plasma free hemoglobin and activated complement. Recently, the company received FDA investigational device exemption (IDE) approval to begin enrollment of its pivotal REFRESH 2 trial intended to support U.S. regulatory approval. CytoSorb® has been used in more than 31,000 human treatments to date.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of nearly $22 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL™, HemoDefend™, VetResQ™, K+ontrol™, ContrastSorb, DrugSorb, and others. For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.